Aug 20 (Reuters) – AstraZeneca (AZN.L) said on Friday its antibody therapy met the main goal of preventing COVID-19 disease in a late-stage study, putting the British drugmaker on track to potentially offer an alternative to vaccines for people with weakened…

Click here to view the original article.